Multiple Myeloma Market Outlook, Size, Share, Key Trends, and Forecast 2032

The global multiple myeloma market reached USD 27.58 billion in 2024 and is projected to grow to USD 44.19 billion by 2032, with a 6.1% compound annual growth rate. Key findings from the market analysis: North America dominates with 58.3% market share in 2024, driven by high treatment demand and advanced therapeutics adoption Immunomodulators lead the drug class segments due to successful treatments like Revlimid Hospital pharmacies are the primary distribution channel due to intravenous drug administration requirements Market drivers include: Rising multiple myeloma prevalence globally Strong pipeline of new therapeutics from companies like Regeneron Increasing product launches and regulatory approvals Key challenges: High treatment costs limiting access in developing countries, with annual costs ranging from $5,800 for cyclophosphamide to $192,000 for Pomalyst Recent developments include FDA approvals of: Sarclisa (isatuximab-irfc) in March 2020 Xpovio (selinexor) in July 2019 Report- Fortune Business Insights - Multiple Myeloma Market Size, Share & Trends Report, 2032 https://www.fortunebusinessinsights.com/multiple-myeloma-market-102693